Sign In
Buy AQST
$4.03
+0.100 (+2.54%)
At Close: Jun 03, 2026
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDA
New York, New York--(Newsfile Corp. - March 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Ther
Portnoy Law Firm Announces Class Action on Behalf of Aquestive Therapeutics, Inc. Investors
07:01pm, Wednesday, 11'th Mar 2026
LOS ANGELES, March 11, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Aquestive Therapeutics, Inc., (“Aquestive” or the "Company") (NASDAQ: AQST) investors off a class action on behalf of
AQST Investors Encouraged to Seek Lead Plaintiff Role in Aquestive Therapeutics Securities Class Action Case with Johnson Fistel
10:41am, Wednesday, 11'th Mar 2026
SAN DIEGO, March 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Aquestive Therapeutic
Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval
02:46am, Wednesday, 11'th Mar 2026
Aquestive Therapeutics remains a Buy, with an $8 fair value estimate and 87% upside, driven by Anaphylm's FDA approval prospects. Anaphylm's CRL issues are addressable, focused on packaging and labeli
Aquestive Therapeutics Targets Q3 Anaphylm Resubmission After FDA CRL Flags Human Factors, PK Data
02:36am, Wednesday, 11'th Mar 2026
Aquestive Therapeutics (NASDAQ: AQST) executives used the Citizens Life Sciences Conference to outline the company's path forward after receiving a Complete Response Letter (CRL) from the U.S. Food an
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics,
Rosen Law Firm Urges Aquestive Therapeutics, Inc. (NASDAQ: AQST) Stockholders to Contact the Firm for Information About Their Rights
07:26pm, Tuesday, 10'th Mar 2026
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) betw
NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP alerts investors in Aquestive Therapeutics, Inc. (NASDAQ: AQST) that Daniel Barber, the Company's Chief Executive Officer, President, and Director, is
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their Options If you purchased or acquir
Class Action Filed Against Aquestive Therapeutics, Inc. (AQST) Seeking Recovery for Investors - Contact The Gross Law Firm
09:00am, Tuesday, 10'th Mar 2026
NEW YORK, March 10, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST). Shareholders who purchased shares of AQST durin
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or a
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
04:01pm, Monday, 09'th Mar 2026
WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful im
SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aquestive Therapeutics, Inc
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their Options If you purchased or acquir
